Lab managers in drug discovery and development can now access a cutting-edge tool to modernize their preclinical workflows: CN Bio’s PhysioMimix® Bioavailability Assay Kit: Human 18. Tailored for the PhysioMimix Multi-organ System, the kit simplifies the complex task of predicting human oral bioavailability, reducing inefficiencies and advancing research capabilities.
Benefits for lab managers
This innovative kit offers substantial advantages for labs focused on accelerating drug development:
- Simplified Onboarding: Ready-to-use design eliminates assay development and validation bottlenecks.
- Accurate Insights: Mimics human bioavailability processes for better lead candidate selection.
- Scalable and Efficient: Supports up to 18 replicates, improving throughput without compromising quality.
- Cost and Resource Optimization: Reduces reliance on animal testing and optimizes in vivo study designs.
Dr. Yassen Abbas, Lead Scientist at CN Bio, emphasizes, “Human bioavailability is a crucial part of choosing which drug candidates to progress to the clinic, but an area that is notoriously poorly served by existing models. The PhysioMimix Bioavailability assay kit: Human 18 effectively tackles this issue, providing up to 18 replicates for our customers to profile their drug candidates in vitro, minimizing risk and maximizing the chance of clinical success. The kit modernizes workflows by removing the burden of assay development and validation, so researchers can rapidly onboard an OOC approach.”
This innovation empowers lab managers to enhance operational efficiency, accelerate project timelines, and improve the predictability of clinical outcomes.
